Author

Yunhui Cheng

University of Michigan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:ChIP-seq· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Abhijit ParoliaiD· 2 shared Arul M. ChinnaiyaniD· 2 shared Jean Ching-Yi TieniD· 2 shared Jie LuoiD· 2 shared Lanbo XiaoiD· 2 shared Rahul MannaniD· 2 shared Sanjana EyunniiD· 2 shared Somnath MahapatraiD· 2 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Abhijit ParoliaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer

Jie Luo, Zhixiang Chen, Yuanyuan Qiao, Jean Ching-Yi Tien, Eleanor Young, Rahul Mannan, Somnath Mahapatra, Rupam Bhattacharyya, Lanbo Xiao, Tongchen He, Sanjana Eyunni, Yuping Zhang, Yang Zheng, Fengyun Su, Xuhong Cao, , Arul M. Chinnaiyan

This study shows that degrading p300/CBP in prostate cancer suppresses tumor growth more effectively than inhibiting their activity, highlighting their role in maintaining the active AR enhanceosome.

Nature Genetics · Oct 1, 2025Peer-reviewedCancer Biology

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

Jean Ching-Yi Tien, Jie Luo, Yu Chang, Yuping Zhang, Yunhui Cheng, Xiaoju Wang, Jianzhang Yang, Rahul Mannan, Somnath Mahapatra, Palak Shah, Xiao-Ming Wang, Abigail J. Todd, Sanjana Eyunni, Caleb Cheng, Ryan James Rebernick, , Arul M. Chinnaiyan

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

Cell Reports Medicine · Oct 1, 2024Peer-reviewedCancer Biology